# Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis.

**Tumor:** Cáncer de esófago
**Autores:** de Pascale S
**Revista:** Cancers (Basel) (2021)
**PMID:** 33562316 | **PMCID:** PMC7915215
**DOI:** [10.3390/cancers13040666](https://doi.org/10.3390/cancers13040666)
**Fuente:** PubMed Central (open access)

## Relevancia
Cáncer de esófago/UGE tras quimiorradioterapia CROSS o quimioterapia FLOT: aborda pCR ganglionar, supervivencia según yp-stage y patrones de diseminación nodal. Análogo a mama: el ypN0 es el factor pronóstico independiente más robusto tras tratamiento neoadyuvante.

## Abstract
After CROSS, neo-adjuvant chemoradiotherapy became the standard for locally advanced cancers of esophagus and gastroesophageal junction (GEJ). This study evaluated the relation between pathological (yp) stage after CROSS regimen followed by surgery for adenocarcinoma of cardia and OS/DFS. The study included 132 patients. The 50-month OS and DFS were 45% and 6.7% respectively. Time to relapse was significantly longer for ypN0 vs ypN+. Chemoradiotherapy in a neoadjuvant setting may influence the site of relapse, significantly reducing local recurrences.

## Acceso
Disponible en PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC7915215/

---
*Datos de PubMed. Citar: doi 10.3390/cancers13040666*
